





This antibody was developed and validated by the Medical Research Council Protein Phosphorylation and **Ubiquitylation Unit (University of** Dundee, Dundee, UK).

## **Background**

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including the regulated and targeted proteasome-dependent degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). Triad Domain-Containing Protein 1 (TRIAD1) is a member of the E3 protein ligase family and cloning of the human gene was first described by van der Reijden et al. (1999). TRIAD1 contains a TRIAD motif containing two RING domains which flank a conserved cysteine-rich (C6HC) domain designated DRIL (double RING finger-linked domain) (Marteijn et al., 2005). TRIAD is thought to be involved in protein translation, interacting with UbcH7 (UBE2L3) to polyubiquitylate elF4E2 targeting it for proteasomal degradation (Tan et al., 2003). More recently these proteins have been referred to as Ring in-between Ring E3 ligases (RBRs) that function like RING-HECT hybrids regulating processes such as translation and immune signalling (Wenzel et al., 2011).

### **Antibody Production:**

Anti-TRIAD1 (human) polyclonal antibody was raised in sheep against TRIAD1 (residues 1-493 of human TRIAD1). The antibodies were

# TRIAD1 (human; full length), pAb

Alternate Names: Triad domain-containing protein 1; Drosophila Ariadne homolog 2; ARIH2

Cat. No. 68-0023-100 Quantity: 100 µg -20°C Lot. No. 30260 Storage:

FOR RESEARCH USE ONLY NOT FOR USE IN HUMANS

**CERTIFICATE OF ANALYSIS** Page 1 of 2

## **Physical Characteristics**

Quantity: 100 µg

Concentration: to be provided on

shipping

Source: sheep polyclonal antibody

Immunogen: human TRIAD1 (residues

1 - 493)

Purification: affinity-purified using

immobilized immunogen

Formulation: phosphate-buffered

**Specificity:** detects TRIAD1 at

~58 kDa

Reactivity: human, chicken and

mouse

Stability/Storage: 12 months at

-20°C; aliquot as required

### **Research Applications and Quality Assurance**

Western Immunoblotting: Use 0.1-0.5 µg/ml

Immunoprecipitation: Use 2.0 µg/mg of cell extract

RNA interference experiment in U2OS cells showing specificity of antibody:

siRNA:

Blot: TRIAD1

#### Western Blotting Analysis:

U2OS cells were transfected with control siRNA, TRIAD1-1 siRNA, TRIAD1-2 siRNA or TRIAD1-3 siRNA (lanes 1, 2, 3 and 4 respectively). By Western blotting the specific recognition of a band corresponding to TRIAD1 was observed in lysates treated with control siRNA (lane 1) compared to lysates treated with TRIAD1-1-3 siRNAs where the presence of TRIAD1 could either not be detected (lane 2) or was significantly reduced (lanes 3 and 4) when probed with 0.5 μg/ml anti-TRIAD1 antibody (Cat# 68-0023-100).

Continued on page 2



### **ORDERS / SALES SUPPORT**

International: +1-617-245-0020 US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)

Email: sales.support@ubiquigent.com

### **UK HQ and TECHNICAL SUPPORT**

International: +44 (0) 1382 381147 (9AM-5PM UTC) US/Canada: +1-617-245-0020 (9AM-5PM UTC)

Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© **Ubiquigent 2014**. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0







## **Background**

Continued from page 1

purified by the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU, University of Dundee, Dundee, U.K.) by affinity purification of the anti-TRIAD1 pAbs from the sheep serum using a GST-tagged antigen-agarose column. Anti-TRIAD1 (human) pAb was sourced by Ubiquigent directly from the MRC-PPU.

#### **General References:**

Marteijn JA, van Emst L, Erpelinck-Verschueren CA, Nikoloski G, Menke A, de Witte T, Lowenberg B, Jansen JH, van der Reijden BA (2005) The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells. *Blood* **106**, 4114-23.

Tan NG, Ardley HC, Scott GB, Rose SA, Markham AF, Robinson PA (2003) Human homologue of ariadne promotes the ubiquitylation of translation initiation factor 4E homologous protein, 4EHP. FEBS Lett 554, 501-4.

van der Reijden BA, Erpelinck-Verschueren CA, Lowenberg B, Jansen JH (1999) TRIADs: a new class of proteins with a novel cysteine-rich signature. *Protein Sci* 8, 1557-61.

Wenzel DM, Lissounov A, Brzovic PS, Klevit RE (2011) UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. *Nature* **474**, 105-8.

### Application Reference:

Kelsall IR, Duda DM, Olszewski JL, Hofmann K, Knebel A, Langevin F, Wood N, Wrightman M, Schulman BA, and Alpi AF (2013) TRIAD1 and HHARI bind to and are activated by distinct neddylated Cullin-RING ligase complexes. *EMBO J* 32, 2848-60.

# TRIAD1 (human; full length), pAb

Alternate Names: Triad domain-containing protein 1; Drosophila Ariadne homolog 2; ARIH2

**Cat. No. 68-0023-100** Quantity: 100 μg **Lot. No. 30260** Storage: -20°C

FOR RESEARCH USE ONLY NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS Page 2 of 2



International: +1-617-245-0020

US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) Email: sales.support@ubiquigent.com **UK HQ and TECHNICAL SUPPORT** 

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0



Dundee, Scotland, UK